| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We previously developed a 95-gene classifier (95GC) to classify ER-positive, HER2-negative, and node-negative breast cancers as high and low-risk groups. Although the 95GC was originally developed using fresh-frozen (FF) tissues, we aimed to apply this to formalin-fixed paraffin-embedded (FFPE) tissues.
As the result, 95GC Recurrence Score was well correlated (R = 0.92) with FF and FFPE tissues, and the concordance rate (94.6%) of high- and low-risk groups was also considerably high. Our 95GC was applicable to FFPE tissues with a high concordance rate with FF tissues.
|
